Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Down 21.3% in January

Aethlon Medical, Inc. (NASDAQ:AEMD) saw a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,370,000 shares, a decline of 21.3% from the January 15th total of 1,740,000 shares. Based on an average trading volume of 3,200,000 shares, the short-interest ratio is currently 0.4 days.

Analysts Set New Price Targets

A number of equities analysts have weighed in on AEMD shares. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Aethlon Medical in a research note on Thursday, January 30th. StockNews.com started coverage on shares of Aethlon Medical in a research note on Monday, January 27th. They issued a “sell” rating for the company.

Aethlon Medical Price Performance

AEMD opened at $0.62 on Monday. The company has a market cap of $8.59 million, a price-to-earnings ratio of -0.22 and a beta of 1.88. The firm has a 50 day simple moving average of $0.63 and a 200 day simple moving average of $0.48. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $1.85.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. As a group, analysts expect that Aethlon Medical will post -1.01 EPS for the current year.

Institutional Investors Weigh In On Aethlon Medical

A number of institutional investors and hedge funds have recently modified their holdings of AEMD. Renaissance Technologies LLC bought a new stake in shares of Aethlon Medical during the fourth quarter worth approximately $25,000. Allegiance Financial Group Advisory Services LLC bought a new stake in Aethlon Medical in the fourth quarter valued at approximately $26,000. Sassicaia Capital Advisers LLC bought a new stake in Aethlon Medical in the fourth quarter valued at approximately $31,000. Virtu Financial LLC bought a new stake in Aethlon Medical in the fourth quarter valued at approximately $81,000. Finally, Boothbay Fund Management LLC bought a new stake in Aethlon Medical in the fourth quarter valued at approximately $186,000. 1.99% of the stock is owned by institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.